Previous Article | Next Article ![]()
Journal of Virology, December 2005, p. 14971-14975, Vol. 79, No. 23
0022-538X/05/$08.00+0 doi:10.1128/JVI.79.23.14971-14975.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
,
M. Buchholz,2,
,
A. Neubauer,3
W. Schulz-Schaeffer,2
M. Groschup,4
S. Walter,1
S. Arendt,2
M. Neumann,1
A. K. Voss,5,¶ and
H. A. Kretzschmar1*
University of Munich, Institute of Neuropathology, Feodor-Lynen-Strasse 23, 81377 München, Germany,1 University of Göttingen, Institute of Neuropathology, Robert-Koch-Strasse 40, 37077 Göttingen, Germany,2 University of Munich, Institute for Medical Microbiology, Infectious and Epidemic Diseases, Veterinärstrasse 13, 80539 Munich, Germany,3 Federal Research Centre for Virus Diseases of Animals, Institute for New and Emerging Diseases, Isle of Riems, Germany,4 Max Planck Institute for Biophysical Chemistry, Department of Molecular Cell Biology, Göttingen, Germany5
Received 28 December 2004/ Accepted 24 August 2005
|
|
|---|
|
|
|---|
Experimental transmission to laboratory rodents has been achieved with TSE agents from many naturally affected species. In these studies, the concept of the species barrier was developed, which refers to the relative resistance to disease encountered following experimental inoculation with TSE agents derived from a different species (21). The adaptation of a TSE agent to its new host requires one or more passages. The species barrier can be quantified by the reduction in the incubation time between primary and secondary passage in the new host.
Transmissible mink encephalopathy (TME) of the North American mink (Mustela vison) was first recognized in 1947 and subsequently described as a TSE in 1965 by Hartsough and Burger (13, 19). Only very few outbreaks of this disease in farmed mink have been described and the cause for these outbreaks is unknown. As scrapie and BSE were experimentally transmitted to mink and, vice versa, TME was transmitted to sheep and cattle, a causal link between the ruminant diseases and TME seems plausible (11, 12, 24, 25). TME was experimentally transmitted to hamsters, but has never been successfully transmitted to mice (2, 18, 30). The species barrier between TME and mice could therefore be termed as an absolute one.
The coding region of the mink PrP gene was sequenced and the deduced amino acid sequence showed a similarity to mouse PrPC of around 90% in the mature protein (17) (Fig. 1A). There is strong evidence that transmission of TSEs is tightly controlled by the PrP-encoding gene (PRNP for humans, Prnp for mice and PrP gene for all other species). Studies with transgenic animals have shown that the species barrier encountered during transmission from nonmurine TSE strains to mice is overcome by introducing the respective nonmurine PrP gene into mice (5, 8, 26, 28, 29, 34). Subsequent investigations, however, have revealed that the expression of a donor-derived PrP transgene may not always be sufficient to erase the species barrier to TSE transmissions and host and strain-specific factors may play a role as well (6, 14, 31, 32).
![]() View larger version (18K): [in a new window] |
FIG. 1. (A) Sequence comparison between murine and mink PrP. The sequence of the murine Prnpa allele (36) is shown and differences in the mink PrP sequence (17) are indicated underneath. The numbering is according to the murine PrP. The single letter code for amino acids is used and only the sequences of the mature PrP devoid of the N- and C-terminal signal peptides are shown. Amino acids proposed to be involved in protein X-binding (15) are underlined and amino acids proposed to be involved in the PrPSc/PrPC interface (28) are highlighted in bold and italics. (B) Schematic representation of cosMink. Exonic sequences of the hamster PrP gene are represented by white boxes and the coding region of the mink PrP gene is highlighted in gray.
|
Generation of transgenic mice. The construct cosMink was derived from the vector cosSHa.Tet (27) and contained the coding region of the mink PrP gene under the control of the hamster PrP gene promoter (Fig. 1B). The vector does not contain the gene coding for Doppel (20). The large NotI fragment of cosMink was injected into fertilized oocytes of either FVB or C57BL/6 mice. The offspring was screened for the presence of the transgene by using PCR and four founder animals were identified (MK7, MK27, MK39, and MK45). The copy number of the transgene was determined by a densitometric analysis of a Southern blot hybridization of EcoRI-digested genomic DNA (Table 1). Expression of the transgene in brain tissue was detected by Western blot analysis using the antibody L42 (35). The expression levels of the transgenic protein in MK7, MK27, and MK45 were compared with the expression of PrP in the brain of an American mink and were 200%, 50%, and 100% respectively, while no synthesis of the transgenic protein was visible in MK39 (Table 1; Fig. 2).
|
View this table: [in a new window] |
TABLE 1. Transgenic mouse lines carrying the mink PrP gene
|
![]() View larger version (54K): [in a new window] |
FIG. 2. Western blot analysis of transgenic mouse lines carrying the mink PrP gene. Brain homogenates of F1 animals of the four different transgenic lines carrying the mink PrP gene, MK7, MK27, MK39, and MK45 were analyzed alongside of North American mink and tg20, a transgenic mouse line overexpressing the murine Prnp (9). Antibody L42 was used as primary antibody in the Western blot analysis following SDS-PAGE. Molecular size markers are indicated to the right of the blot and estimates of the amount of mink PrP in the different transgenic lines compared to the mink are indicated underneath.
|
The TME agent did not infect C57BL/6 or FVB inbred mice after more than 800 days (Table 2). In contrast, transgenic mice expressing the mink PrP gene on a Prnp0/0 background were readily infected with the TME agent and succumbed to disease with a mean incubation time of 164 days (MK7/Prnp0/0) or 312 days (MK45/Prnp0/0). The absolute species barrier of mice towards the TME agent was therefore broken by the introduction of the mink PrP gene and the incubation time was inversely proportional to the level of mink PrP gene expression.
|
View this table: [in a new window] |
TABLE 2. Susceptibility of transgenic mouse lines carrying the mink PrP gene to TME and 79A
|
Brain material of terminally ill MK7/Prnp0/0 and MK45/Prnp0/0 mice infected with TME was inoculated into MK7/Prnp0/0 mice in a secondary transmission (Table 2). Both transmission experiments showed remarkable similar mean incubation times of 147 or 148 days, which is slightly shorter than 164 days of the primary transmission of TME into MK7/Prnp0/0 mice. This indicated that there may be a small species barrier to overcome in the primary transmission, but reliable estimate of the titers in the primary and secondary passage will require titration experiments.
Histopathological examination revealed massive spongiosis, neuronal loss and gliosis in the cortex of MK7/Prnp0/0 mice (Fig. 3), while these changes were completely absent in mock-infected animals (data not shown). Immunohistochemical examination using antibody L42 revealed strong deposition of the mink PrPSc in the cortex and delicate granular staining in the cerebellum (Fig. 3). Quite distinctly, the Purkinje cells were devoid of staining. A mock-infected MK7/Prnp0/0 mouse did not show detectable PrPSc deposition (data not shown).
![]() View larger version (117K): [in a new window] |
FIG. 3. Histopathological analysis of infected MK7/Prnp0/0 mice. (A) Cerebral cortex showing numerous delicate vacuoles (spongiform change) stained with hematoxylin and eosin Original magnification, x20. (B) Cerebellum showing strong immunostaining for PrPSc in red in the molecular and internal granule cell layer using L42 as primary antibody. Original magnification, x10.
|
![]() View larger version (45K): [in a new window] |
FIG. 4. Western blot analysis of PK-resistant PrP in brain homogenates of infected animals. (A) Brain homogenates of transgenic mice (MK45/FVB, MK7/FVB) infected with 79A were compared to normal mice (C57/Black6) infected with the same agent as well as to Mk7/Prnp0/0 mice and mink infected with TME. Homogenates were either treated with PK (+) or left untreated (). The upper panel was immunostained using L42 as primary antibody, while the lower panel was stained using Ra3153. A molecular marker was loaded in the left lane, and the molecular sizes are indicated. (B) Brain homogenates of normal mice (FVB and C57/Black6), transgenic MK7/FVB and mink, all infected with TME, were compared using either L42 (upper panel) or Ra3153 (lower panel) as the primary antibody.
|
Infection of lines MK7 and MK45 with TME on a murine PrP background. In a separate line of breeding, the transgenic animals were crossed with nontransgenic inbred mice (FVB) instead of Prnp0/0 mice. These mice produced the mink PrP along with with the murine PrP and were inoculated with the TME agent and scrapie strain 79A. The TME agent caused disease in MK7/FVB mice after a mean incubation time of 459 days, which was dramatically prolonged compared with the incubation time of 164 days in MK7/Prnp0/0 mice (Table 2). TME did not cause disease in the lower-expressing MK45/FVB within 800 days. The presence of the endogenous murine PrP had therefore a strong inhibitory effect on the disease progression of TME in mice expressing mink PrP genes.
In sharp contrast to the TME agent, the mouse-adapted scrapie strain 79A infected both transgenic lines on normal background with a mean incubation time of 149 (MK7/FVB) and 167 days (MK45/FVB). These incubation times are comparable to or even slightly shorter than the 173 days following infection of normal mice with 79A. The presence of the mink transgene had therefore no recognizable inhibitory effect on the efficiency of the infection of 79A in mice.
The analysis of the brain homogenates without PK digestion showed that indeed PrP of both species was present in transgenic mice on a murine PrP-normal background (Fig. 4A for MK7/FVB mice and MK45/FVB mice infected with 79A and Fig. 4B for MK7/FVB mice infected with TME), while after PK digestion, only murine PrPSc was visible in 79A-infected mice (Fig. 4A) and only mink PrPSc could be detected in TME infected animals (Fig. 4B). Similar to an experiment expressing the hamster PrP gene in transgenic mice and infecting them with either hamster- or mouse-adapted scrapie (22), the infecting agent determined the type of PrP that accumulated in the brain of the diseased transgenic mouse. It is particularly noteworthy that also the banding pattern of the PK-resistant PrP corresponded the pattern of the inoculum. This banding pattern is considered as a strain signature and it has been shown in experimentally infected normal and transgenic mice to be faithfully transmitted (7, 16, 33).
One possible hypothesis that would explain these findings in mice producing both mink and mouse PrPC is that mouse PrPSc does not interact with mink PrPC and, therefore, the interaction of the incoming mouse PrPSc (79A) with the homologous mouse PrPC can progress with the same efficiency as in the absence of mink PrP, i.e., in the normal mouse. The incoming mink PrPSc (TME), however, can interact with mouse PrPC, but the conversion of this heterologous complex either cannot progress efficiently or converted mouse PrPSc cannot bind mouse or mink PrPC or, if bound, cannot convert mink or mouse PrPC. The homologous mink PrP conversion takes place, but is much less efficient in the presence of endogenous mouse PrPC than without mouse PrPC, i.e., in the MK7-mice on a Prnp0/0 background. It is important to note that the amino acid residues 183, 202, and 204 (numbering according to the murine PrP), which define part of the PrPC/PrPSc interface according to the publication by Scott and colleagues (28), all differ between the murine and the mink PrP. The nature of the interaction between the mink PrPC and the mouse PrPSc or the mouse PrPC and the mink PrPSc or lack thereof could be tested in in vitro conversion assays.
This work was supported by the German Ministry of Education and Research, the European Commission, and the State of Bavaria.
O.W. and M.B. contributed equally to this work. ![]()
Present address: Veterinary Laboratories Agency, New Haw, Addlestone, Surrey, United Kingdom. ![]()
Present address: University of Ulm, Department of Internal Medicine I, Robert-Koch-Str. 8, 89081 Ulm, Germany. ![]()
¶ Present address: Walter and Eliza Hall Institute, IG Royal Parade, Parkville, Victoria 3050, Australia. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»